| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025年期初占用 | 2025年1-6月占用累计发 | 2025年1-6月度占用资 | 2025年1-6月度偿还 | 2025年6月期末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 资金余额 | 生金额（不含利息） | 金的利息(如有) | 累计发生金额 | 占用资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控制人及其附属企 | | | | | | | | | | 非经营性占用 | | 业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 其他关 ...

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-088 公司监事审议了公司 2025 年半年度报告全文及摘要，认为公司半年度报告 真实、准确、完整地反映了公司 2025 年上半年度经营状况，不存在虚假记载、 误导性陈述或重大遗漏。 具 体 内 容 详 见 公 司 同 日 披 露 于 《 证 券 日 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《2025 年半年度报告摘要》，披露于巨潮资讯 网（http://www.cninfo.com.cn）上的《2025 年半年度报告全文》。 表决结果：同意 3 票，反对 0 票，弃权 0 票 三、备查文件 绿康生化股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）第五届监事会 第十四次会议于 2025 年 8 月 28 日以现场方式在公司综合办公楼二楼第二会议室 召开，会议通知已按照《公司章程》及《公司监事会议事规则》要求发出。本次 监事 ...

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-087 绿康生化股份有限公司 第五届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）第五届董事会 第二十一次会议于 2025 年 8 月 28 日在公司综合办公楼二楼第一会议室以现场结 合通讯会议方式召开，会议通知已按照《公司章程》及《公司董事会议事规则》 要求发出。本次董事会应到董事 7 人，实到董事 7 人，其中独立董事 3 人。本次 会议由董事长赖潭平先生主持召开。本次会议的召集、召开、表决程序符合《中 华人民共和国公司法》和《公司章程》的规定，所作决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于公司 2025 年半年度报告全文及摘要的议案》 公司董事会认真审议了公司 2025 年半年度报告全文及摘要，认为公司半年 度报告的编制和审核程序符合法律、法规和中国证监会的规定；报告内容真实、 准确、完整地反映了公司 2025 年上半年度经营状况，不存在虚假记载、误导性 陈述或 ...

Stock Performance and Risks - The company's stock has been under "delisting risk warning" since April 30, 2025, with the stock name changed to "*ST LIFECOME" and a trading limit of 5% on the risk warning board[5]. - The company has faced significant risks, including potential termination of its stock listing if financial indicators trigger specific conditions set by the Shenzhen Stock Exchange[5]. - The company has emphasized the importance of investor caution due to the uncertainties surrounding the completion of the share transfer and asset sale transactions[7][8]. - The company is facing risks from major customer procurement fluctuations, impacting revenue and profitability, and is working to expand its product matrix and stabilize supply chains[74]. - The company is exposed to exchange rate fluctuations, particularly with USD, which could affect its competitive pricing in international markets[75]. - Raw material price volatility, especially for EVA and POE resin particles, poses a risk, and the company plans to diversify procurement channels to mitigate this[75]. Shareholder and Management Changes - On April 24, 2025, the company transferred 46,608,397 shares, representing 29.99% of the total share capital, to Fujian Zongteng Network Co., Ltd., changing the controlling shareholder from Shanghai Kangyi Investment Co., Ltd. to Zongteng Network[7]. - The company reported a significant change in its actual controller from Lai Tanping to Wang Zuan following the share transfer[7]. - The company has undergone changes in its board of directors and management, with several resignations and appointments in 2025[80]. - The company held its 2023 annual shareholder meeting on May 20, 2024, resulting in a change in senior management, reducing the number of participating directors (excluding independent directors) and supervisors to 6[88]. - The company appointed a new board secretary, Lin Xinhong, on May 26, 2025, following the resignation of Huang Kai[88]. Financial Performance - The company's total revenue for the reporting period was CNY 293.87 million, a decrease of 9.97% compared to the same period last year[27]. - The net loss attributable to shareholders was CNY -58.57 million, an improvement of 32.74% from a net loss of CNY -87.08 million in the previous year[27]. - The net cash flow from operating activities increased by 18.69% to CNY 75.38 million, compared to CNY 63.51 million in the same period last year[27]. - The company reported a basic and diluted earnings per share of CNY -0.38, reflecting a 32.14% improvement from CNY -0.56 in the previous year[27]. - The total assets at the end of the reporting period were CNY 1.40 billion, down 6.44% from CNY 1.49 billion at the end of the previous year[27]. - The company’s total equity attributable to shareholders decreased from RMB -26,267,391.62 to RMB -83,026,556.33, indicating a significant decline in shareholder equity[149]. Business Strategy and Operations - The company plans to sell all assets and liabilities related to its photovoltaic film business, including 100% equity of its subsidiaries, to a joint venture company, Jiangxi Raoxin, with the transaction still pending shareholder approval[8]. - The company is actively restructuring its ownership and asset portfolio to address financial challenges and improve operational efficiency[8]. - The company completed the acquisition of Lvkang Yushan and established Lvkang Haining, initiating investment in the photovoltaic film project, forming a dual main business model[34]. - The company has established a dual business model focusing on "animal health products + photovoltaic encapsulation films" for production and sales[41]. - The company is exploring market expansion opportunities, particularly in the export trade sector[122]. Research and Development - The company's R&D investment decreased by 34.40% to ¥12.56 million, attributed to reduced investment in the subsidiary focused on photovoltaic film[52]. - The company is focusing on enhancing its R&D capabilities, with a budget increase of 2.8 million allocated for new technology development[168]. Asset Management and Guarantees - The company aims to optimize its asset structure and improve cash flow, which is crucial for enhancing core competitiveness and sustaining operational capabilities[110]. - The company provided guarantees totaling 3,000 million for various projects, with a specific guarantee amount of 490 million due on November 23, 2023[121]. - The total approved guarantee amount for subsidiaries at the end of the reporting period is 80,200, with an actual guarantee balance of 47,204.98[126]. Compliance and Regulatory Matters - The company is committed to ensuring compliance with regulatory standards, as indicated by its reporting practices[122]. - The company has not reported any significant changes in the number of shares held by strategic investors or general legal persons during the reporting period[137]. - The company has not issued any non-standard audit reports for the current or previous reporting periods[104]. Community Engagement - The company established a charity fund to support impoverished families, donating a total of 32,000 yuan to assist 7 families in the first half of 2025[98].

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Market Overview - The animal health sector experienced a slight decline of 0.03% on August 26, with Shenlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Key stocks in the animal health sector showed varied performance: - KQ Bio (688526) rose by 6.80% to close at 19.33, with a trading volume of 167,100 shares and a turnover of 327 million yuan [1] - Huisheng Biological (300871) increased by 1.48% to 24.00, with a trading volume of 160,900 shares and a turnover of 387 million yuan [1] - Shenlian Biological (688098) fell by 8.41% to 13.28, with a trading volume of 313,100 shares and a turnover of 433 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 68.22 million yuan from institutional investors, while retail investors had a net inflow of 76.14 million yuan [2][3] - Notable capital flows for specific stocks include: - Huisheng Biological had a net outflow of 56.08 million yuan from institutional investors [3] - Zhongmu Co. (600195) experienced a net inflow of 3.88 million yuan from institutional investors [3] - KQ Bio had a net outflow of 20.91 million yuan from institutional investors [3]

终通过审批的时间均存在一定不确定性。公司将根据本次交易的进展情况，严格 按照相关法律法规的规定及时履行信息披露义务，敬请广大投资者及时关注公司 后续公告并注意投资风险。 股票简称由"绿康生化"变更为"*ST 绿康"，证券代码仍为"002868"。 公 司股票在风险警示板交易，股票交易的日涨跌幅限制为 5%。敬请广大投资者注 意投资风险。 证券代码：002868 证券简称：*ST 绿康 公告编号：2025-086 绿康生化股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 于 2025 年 6 月 28 日披露的《绿康生化股份有限公司重大资产出售暨关联交 易报告书（草案）》"重大风险提示"及"第十一节风险因素"中，详细披露了 本次交易可能存在的风险因素及尚需履行的其他程序，敬请广大投资者注意投资 风险。 致公司董事会或者交易对方撤销、中止本次交易或者对本次交易作出实质性变更 的相关事项，本次交易工作正在有序进行中。公司将根据相关事项的进展情况， 及时履行信息披露义务。 截至本公告披露日，公司及相关机构正积极推进本次交易进程。本次交易尚 需提 ...

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-086 绿康生化股份有限公司 关于重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、绿康生化股份有限公司（以下简称"公司""上市公司"或"绿康生化"） 于 2025 年 6 月 28 日披露的《绿康生化股份有限公司重大资产出售暨关联交 易报告书（草案）》"重大风险提示"及"第十一节风险因素"中，详细披露了 本次交易可能存在的风险因素及尚需履行的其他程序，敬请广大投资者注意投资 风险。 2、截至本公告披露之日，除草案披露的风险因素外，公司尚未发现可能导 致公司董事会或者交易对方撤销、中止本次交易或者对本次交易作出实质性变更 的相关事项，本次交易工作正在有序进行中。公司将根据相关事项的进展情况， 及时履行信息披露义务。 3、本次交易尚需提交公司股东会审议，本次交易能否通过上述审批以及最 终通过审批的时间均存在一定不确定性。公司将根据本次交易的进展情况，严格 按照相关法律法规的规定及时履行信息披露义务，敬请广大投资者及时关注公司 后续公告并注意投资风险。 公司于 ...

Market Overview - On August 25, the animal health sector rose by 1.47%, led by Shenlian Biological, while the Shanghai Composite Index closed at 3883.56, up 1.51%, and the Shenzhen Component Index closed at 12441.07, up 2.26% [1]. Stock Performance - Shenlian Biological (688088) closed at 14.50, with a significant increase of 13.81% and a trading volume of 521,000 shares, amounting to 723 million yuan [1]. - Other notable stocks included: - KQ Biological (688526) at 18.10, up 2.67% [1]. - Dayu Biological (871970) at 10.25, up 1.18% [1]. - Huisheng Biological (300871) at 23.75, up 0.93% [1]. - Ruip Biological (300119) at 23.48, up 0.86% [1]. - Jinhai Biological (002688) at 7.31, up 0.55% [1]. Capital Flow - The animal health sector experienced a net outflow of 40.13 million yuan from institutional investors, while retail investors saw a net outflow of 60.97 million yuan. Conversely, speculative funds had a net inflow of 101 million yuan [2]. Individual Stock Capital Flow - Shenlian Biological had a net inflow of 35.39 million yuan from institutional investors, while retail investors faced a net outflow of 74.83 million yuan [3]. - Other stocks with notable capital flows included: - Pulaike (603566) with a net inflow of 3.28 million yuan from institutional investors and a net outflow of 9.68 million yuan from retail investors [3]. - Huisheng Biological (300871) had a net inflow of 2.55 million yuan from institutional investors but a net outflow of 13.77 million yuan from retail investors [3].